Day 4:

Vistonuridine: A Life-saving Antidote for 5FU Overdose

VeriStrat Test Advances Personalized Medicine on the Head and Neck Cancer Front: Interview with Dr Ezra Cohen (Podcast)

Early Chemotherapy for Ovarian Cancer Relapse Based on Serial CA-125 Monitoring does Not Improve Overall Survival or Quality of Life

Does Maintenance Therapy Improve Survival in NSCLC?

HPV Infection Increases Survival in Oropharyngeal Cancers

Antidepressants Often Prescribed with Tamoxifen can Double Risk of Breast Cancer Recurrence

Two Studies on Novel Drug Neratinib (HKI-272) Demonstrate Clinical Benefit in HER2-Positive Breast Cancer

Should Head and Neck Cancer Patients Receive Induction Chemotherapy Prior to Chemoradiotherapy?

Small Study Identifies Eight Genes that Predict Response in Metastatic Melanoma

---

Day 3:

Personalized Vaccine with Patient's Own Tumor Cells Prolongs Survival in Follicular Lymphoma Compared to Control Vaccine

Fertility Issues Must be Addressed by Oncologists

Novel Therapeutic Agent Shows Promise for Treating Triple Negative Breast Cancer

Interview with Nicholas J. Robert, MD, Operations Co-Chair, Breast Cancer Research Committee, US Oncology Research, Inc. (Podcast)

Trastuzumab (Herceptin) Increases Overall Survival in HER2-Positive Gastric Cancer

---

Day 2:

Discoveries in Prostate Cancer that may Eventually Help Personalize Care

Oncologists Need to Discuss the Costs of Cancer Care

Vaccine Appears Promising for Advanced Melanoma

New Tool for Patients with Cancer

Surgery may not Be Necessary for Late-stage Colorectal Cancers

Failure in Bevacizumab (Avastin) Early Stage Colon Cancer NSABP Trial May Not Be Absolute

High Death Rate from NSCLC in Postmenopausal Women Who Smoke and Use Combination Hormonal Therapy

---

Day 1:

Stimulus Funds Provide a Temporary Boon to Cancer Research

Predicting Therapy Response in ALL Patients May Come Down to 9 Genes

More Evidence to Support Personalized Cancer Care as Researchers Show EGFR Biomarkers Correlate with Response to Gefinitib

Ginger in Combination with Traditional Antiemetics Prevents CINV

Affording Supportive Care Medications Hard for 10% of Patients in Cancer Trials; Better Communication with Physicians Needed